Cargando…
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
Patients with decompensated cirrhosis, particularly those with acute‐on‐chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma metabolites of patients with decompensated...
Autores principales: | Pose, Elisa, Solà, Elsa, Lozano, Juan J., Juanola, Adrià, Sidorova, Julia, Zaccherini, Giacomo, de Wit, Koos, Uschner, Frank, Tonon, Marta, Kazankov, Konstantin, Jiménez, Cesar, Campion, Daniela, Napoleone, Laura, Ma, Ann T., Carol, Marta, Morales‐Ruiz, Manuel, Alessandria, Carlo, Beuers, Ulrich, Caraceni, Paolo, Francoz, Claire, Durand, François, Mookerjee, Rajeshwar P., Trebicka, Jonel, Vargas, Victor, Piano, Salvatore, Watson, Hugh, Abraldes, Juan G., Kamath, Patrick S., Davis, Mark M., Ginès, Pere |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035579/ https://www.ncbi.nlm.nih.gov/pubmed/34964311 http://dx.doi.org/10.1002/hep4.1881 |
Ejemplares similares
-
The Use of Rifaximin in Patients With Cirrhosis
por: Caraceni, Paolo, et al.
Publicado: (2021) -
Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial
por: Madsen, Bjørn Stæhr, et al.
Publicado: (2018) -
Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction
por: Sauerbruch, Tilman, et al.
Publicado: (2021) -
Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life
por: Carol, Marta, et al.
Publicado: (2022) -
A novel smartphone scleral‐image based tool for assessing jaundice in decompensated cirrhosis patients
por: Kazankov, Konstantin, et al.
Publicado: (2023)